Human papillomavirus-associated diseases encompass a range of conditions, including cervical, oropharyngeal, and anogenital cancers. These diseases account for a significant global health burden, with a pooled prevalence of 31% for any HPV and 21% for high-risk HPV. HPV-16 remains the most common genotype at 5%, followed by HPV-6 at 4%. There is a high unmet clinical need for improved therapies, as current treatment options, such as surgery and radiation, have limitations. The growing focus on immunotherapies, targeted therapies, and HPV-specific therapeutic vaccines is expected to drive advancements in human papillomavirus-associated diseases drug development, expanding the treatment pipeline in the coming years.
Major companies involved in the human papillomavirus associated diseases pipeline drugs market include Antiva Biosciences, Labo'Life, and others.
Leading drugs currently in the pipeline include 2LPAPI®, ABI-2280, and others.
The rising prevalence of high-risk HPV strains and the growing investment in HPV-specific therapeutic vaccines and innovative treatments are driving the expansion of the human papillomavirus-associated pipeline landscape.
The Human Papillomavirus Associated Diseases Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into human papillomavirus-associated diseases therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human papillomavirus-associated diseases. The human papillomavirus-associated diseases report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The human papillomavirus-associated diseases pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with human papillomavirus-associated disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to human papillomavirus-associated diseases.
Human papillomavirus-associated diseases include cervical, oropharyngeal, anal, and genital cancers, as well as warts. It spreads through skin-to-skin and sexual contact, with high-risk strains causing malignancies. Persistent infection with oncogenic HPV types, particularly HPV-16 and HPV-18, leads to cellular changes, increasing the risk of cancer development over time.
Human papillomavirus-associated diseases are treated with surgical excision, radiation, and chemotherapy for cancerous lesions. Immunotherapies, targeted drugs, and HPV vaccines aid prevention and treatment. Advanced therapies, including therapeutic vaccines and antiviral agents, are in development to address unmet clinical needs and improve outcomes for HPV-related conditions.
The global prevalence of human papillomavirus is 31% for any HPV and 21% for high-risk strains. HPV-16 is the most common genotype at 5%, followed by HPV-6 at 4%. Nearly one in three men worldwide have at least one genital HPV type, while one in five carries high-risk strains. Cervical HPV prevalence is highest in Latin America and the Caribbean at 16%, Eastern Europe at 14%, and Southeast Asia at 14%. The increasing focus on immunotherapies, targeted treatments, and HPV-specific vaccines is expected to drive significant advancements in therapeutics for HPV-associated diseases.
This section of the report covers the analysis of human papillomavirus-associated diseases drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total human papillomavirus-associated diseases clinical trials.
The drug molecule categories covered under the human papillomavirus-associated diseases pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapies, and others. The human papillomavirus-associated diseases report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus-associated diseases.
The EMR report for the human papillomavirus-associated diseases drug pipeline includes the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed human papillomavirus-associated diseases therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is a list of a few players involved in human papillomavirus-associated diseases clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for human papillomavirus-associated diseases. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of human papillomavirus-associated disease drug candidates.
2LPAPI®, a novel treatment belonging to the immunotherapy drug class, is being evaluated in a Phase IV clinical trial sponsored by Labo'Life. The study aims to assess its efficacy in clearing genital high-risk human papillomavirus (HR-HPV) infections. This randomized, placebo-controlled study will enroll approximately 284 participants.
ABI-2280 vaginal inserts, developed by Antiva Biosciences, are being evaluated in a Phase Ib/II study to assess their safety, tolerability, and efficacy in women with persistent high-risk human papillomavirus (HPV) infections. The study aims to assess viral clearance and optimal dosing regimens. Expected to conclude by February 2026, the trial plans to enroll an estimated 160 participants across multiple cohorts.
NEXI-003, an autologous T-cell therapy targeting HPV-16, HPV-18, and Survivin, is being evaluated in a Phase I trial sponsored by NexImmune Inc. The study aims to assess the safety of NEXI-003 in patients with relapsed or refractory HPV-related oropharyngeal cancers. It is expected to conclude by August 2027 and intends to recruit around 36 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Human Papillomavirus Associated Diseases Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus-associated diseases. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into human papillomavirus-associated diseases collaborations, regulatory environments, and potential growth opportunities.
Global Human Papillomavirus (HPV) Vaccine Market
Human Papillomavirus (HPV) Drug Pipeline Analysis
Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share